By Mary Kangley 
Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| July Rank | June Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 36,525 | 1,700 | 68 |
| 2 | 2 | AstraZeneca | 11,182 | 441 | 13 |
| 3 | 3 | Johnson & Johnson | 5,517 | 446 | 73 |
| 4 | 4 | Biogen | 1,376 | 699 | 0 |
| 5 | 5 | GSK | 656 | 206 | 28 |
| 6 | 8 | Roche | 429 | 158 | 34 |
| 7 | 12 | Bayer | 382 | 132 | 25 |
| 8 | 7 | Gilead | 367 | 88 | 8 |
| 9 | 10 | Sanofi | 366 | 124 | 29 |
| 10 | 6 | Novartis | 311 | 223 | 16 |
| 11 | 14 | Abbott | 292 | 262 | 22 |
| 12 | 13 | Merck & Co | 270 | 159 | 73 |
| 13 | 17 | Boehringer Ingelheim | 232 | 195 | 35 |
| 14 | 11 | Novo Nordisk | 195 | 172 | 33 |
| 15 | 9 | Regeneron | 188 | 86 | 8 |
| 16 | 20 | Otsuka | 169 | 7 | 1 |
| 17 | 15 | Lilly | 168 | 93 | 18 |
| 18 | 22 | Amgen | 101 | 67 | 5 |
| 19 | 19 | AbbVie | 90 | 62 | 9 |
| 20 | 21 | Fresenius | 74 | 40 | 18 |
| 21 | 26 | Teva | 68 | 59 | 29 |
| 22 | 25 | Takeda | 64 | 58 | 10 |
| 23 | 16 | BMS | 59 | 53 | 3 |
| 24 | 27 | Merck KGaA | 58 | 58 | 19 |
| 25 | 24 | Eisai | 47 | 21 | 2 |
| 26 | 18 | Mylan | 43 | 0 | 0 |
| 27 | 29 | CSL | 41 | 36 | 11 |
| 28 | 36 | Allergan | 39 | 1 | 0 |
| 29 | 30 | Chugai | 39 | 2 | 0 |
| 30 | 34 | Astellas | 36 | 26 | 0 |
| 31 | 40 | Sun | 34 | 27 | 18 |
| 32 | 23 | UCB | 24 | 22 | 16 |
| 33 | 35 | Bausch | 23 | 11 | 0 |
| 34 | 32 | Ipsen | 17 | 11 | 7 |
| 35 | 28 | Servier | 16 | 8 | 4 |
| 36 | 37 | Menarini | 15 | 12 | 8 |
| 37 | 39 | Grifols | 14 | 0 | 0 |
| 38 | 31 | Alexion | 13 | 7 | 1 |
| 39 | 33 | Daiichi Sankyo | 12 | 4 | 2 |
| 40 | 38 | Vertex | 9 | 8 | 0 |
| 41 | 50 | Mitsubishi Tanabe Pharma | 5 | 5 | 0 |
| 42 | 47 | Aurobindo | 1 | 0 | 0 |
| 43 | 46 | Endo | 1 | 0 | 0 |
| 44 | 48 | Ono | 1 | 0 | 0 |
| 50 | 45 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 44 | Meiji | 0 | 0 | 0 |
| 50 | 43 | Shanghai | 0 | 0 | 0 |
| 50 | 49 | Sino | 0 | 0 | 0 |
| 50 | 41 | Sumitomo Dainippon | 0 | 0 | 0 |
| 50 | 42 | Yunnan Baiyao | 0 | 0 | 0 |
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
In the month of July, the top five pharmaceutical companies mentioned by healthcare professionals (HCPs) remained the same and were positioned in the same ranking. Pfizer was located first, followed by AstraZeneca, Johnson and Jhonson (J&J), Biogen, and GSK.
Compared to last month, the HCP conversation increased by two percent. The slight increase was seen due to the continuation of HCP discussion about the efficacy of COVID-19 vaccines against the Delta, Alpha, Beta, and Lambda variants. Many HCPs shared data showing the percentage of effectiveness that different vaccines have against these variants, and some showed concern about the high spread of the Delta variant among people that are vaccinated.
I keep hearing scarier & scarier things about the delta COVID variant – like Pfizer is only 64% effective against it & that vaccinated people are spreading it to other vaccinated people – so now I’m even more sure I’ll be wearing a mask indefinitely because this is terrifying.
— NurseKelsey (she/her) 🌈✨🎉❤️🏳️🌈 (@nursekelsey) July 6, 2021
1/🧵 Delta Variant & #Vaccines: @NEJM
These data show that 2 doses of Pfizer (~90%) or AZ (~70%) vaccines are SIMILARLY EFFECTIVE against #Alpha vs #DeltaVariant of #COVID19. One dose was NOT good enough!
https://t.co/vbwo5TkYJR#Medtwitter #Nurse pic.twitter.com/yo71FIKD1A— WesElyMD (@WesElyMD) July 21, 2021
HCPs also shared the news of Pfizer seeking an FDA approval for a “booster shot” after two doses of their vaccine, since there is data showing that the antibody levels decrease after 6 months of being vaccinated. This aim is to prevent the continued spread of the Delta variant, yet some HCPs say that the data is not compelling enough to justify the approval.
Pfizer solicitará a FDA la autorización para poner una tercera dosis de su vacuna como refuerzo, dada la presencia de la variante delta. https://t.co/w5T7niQBaC
Considero que la evidencia actual no justifican el requerimiento. Dudo que la FDA lo autorice con los datos existentes.— Alejandro Macias (@doctormacias) July 9, 2021
Another topic of the HCP conversation was the vaccine roll-out that various governments are undertaking. Some HCPs criticized governments for not giving enough vaccines to the people.
新型コロナウイルスワクチンの来年に向けた供給に係る武田薬品工業株式会社及びモデルナ社との契約締結について
5,000万回分を追加契約https://t.co/393YhKttDHTakeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Governmenthttps://t.co/28lZv9Wweg https://t.co/BFS3TcL2TD pic.twitter.com/GU6pk09Iv8
— Mugen UJIIE (氏家 無限) (@carpe_diem0820) July 20, 2021
The three most shared links by HCPs in July were:
- An article published by NEJM showing the effectiveness of COVID-19 vaccines against the Delta variant.
- A news article from The Times of Israel showing that the Health Ministry of Israel said that even though the Pfizer vaccine is only 64% effective against the Delta variant, it is still effective at preventing serious symptoms and hospitalizations.
- An article from Medrxiv showing a study of the safety and efficacy of the Pfizer vaccine after six months of administration.
The volume of HCP COVID-19 conversation in the context of top 50 pharma increased by about 800 posts from June to July, making up 65% of the overall HCP conversation in July.
Outside the COVID-19 conversation, HCPs discussed a variety of different topics from different therapy areas. J&J was mentioned due to the recalling of the Neutrogena and Aveeno spray sunscreens that were found to have low levels of benzene, a chemical known for causing cancer, in some of their samples. Boehringer was mentioned by HCPs discussing the EMPEROR-Preserve trial results showing Jardiance (empagliflozin) as efficient for treating heart failure with preserved ejection fraction (HFpEF).
Johnson & Johnson is recalling five of its Neutrogena and Aveeno spray sunscreens after they found low levels of benzene, a cancer-causing chemical, in some samples. Calm and Repair contains no toxic ingredients and provides maximal sun protection. https://t.co/Q6qqtsuDFr pic.twitter.com/z1RwCwAa2K
— Julia T. Hunter MD (@JuliaTHunterMD) July 31, 2021
🚨📰EMPEROR-Preserved👏👏
👉 significantly ⤵️⤵️ the risk of the composite of CV death or 🏥 for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF).@secardiologia @IcyfaSemi @BoehringerES pic.twitter.com/DcKf2kgbnZ— Alfonso Valle (@ValleAlfonso) July 6, 2021
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In July 2021, CREATION Pinpoint® identified 53,055 healthcare professional (HCP) authored tweets from 15,336 individual HCPs mentioning a Top 50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between July 1st and July 31st 2021.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In July, 2,186 of these posts mentioned Janssen.
